WI
REGN icon

Westbourne Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Westbourne Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Hold
500
– – 0.18% 102
2025
Q4 		$386K Hold
500
– – 0.18% 101
2025
Q3 		$326K Hold
500
– – 0.16% 96
2025
Q2 		$263K Hold
500
– – 0.14% 116
2025
Q1 		$317K Hold
500
– – 0.19% 104
2024
Q4 		$356K Buy
+500
New +$420K 0.21% 89

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Westbourne Investments's REGN Position: Q1 2026 in Review

Westbourne Investments held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 500 shares worth $386K. The position accounts for 0.18% of the portfolio, ranked #102.

Westbourne Investments first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Westbourne Investments held 500 shares of Regeneron Pharmaceuticals worth $386K as of Q1 2026.
  • Westbourne Investments left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.18% of Westbourne Investments's portfolio in Q1 2026, its #102 holding.
  • Westbourne Investments first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Westbourne Investments's 13F filing for Q1 2026, filed 15 May 2026.